Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.
Reiki Nishimura(Kumamoto City Hospital), Kazuo Tamura(Kindai University), Masayuki Okido, Yasushi Takamatsu, Yoshiaki Rai, Shigeru Imamura, Noriaki Itoyanagi(St. Francis Hospital), Masato Kato(Hamanomachi Hospital), Manabu Kudaka, Fumie Matsuo, Shinsuke Hara, Shoshu Mitsuyama(Kitakyushu Municipal Medical Center), Ryoji Watanabe, Yoshihiko Kamada, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Keisei Anan, Mitsunori Shirouzu
PubMed
August 1, 2012
Cited by 3
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer
|International Journal of Clinical Oncology|2021|157
Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma
|Oncology|2010|102
Non-Invasive Evaluation of Hepatic Fibrosis for Type C Chronic Hepatitis
|Intervirology|2010|79